Stanford researchers find stem cell transplant can grow new immune ...
Bizjournals.com - Charlotte,NC,USA
... and Regenerative Medicine. The study will be published in the Nov. 23 issue of Science. A person with an autoimmune disease such as multiple sclerosis ...
See all stories on this topic

Best Stocks for 2008: Elan (ELN) has 'more room to run'
BloggingStocks - USA
"I originally recommended it in June 2005 at $7 after the company withdrew Tysabri, a multiple sclerosis drug, from the US market. After being reapproved by ...
See all stories on this topic

Montel Williams' new book shares secrets of healthy living
The Birmingham News - al.com - Birmingham,AL,USA
When talk show host Montel Williams was diagnosed with multiple sclerosis he thought his life was over. Doctors told him to quit his show, avoid stress and ...
See all stories on this topic

Lilly in Deal with BioMS for MS Drug
From Reuters Health - Dec 18, 2007
NEW YORK (Reuters) - Eli Lilly and Co said on Monday it has entered a deal that gives it exclusive worldwide rights to an experimental multiple sclerosis drug being developed by Canada's BioMS Medical Corp. The drug, MBP8298, is currently in late-stage clinical trials for secondary progressive multiple sclerosis (MS) and in mid-stage trials for relapsing-remitting MS, the companies said.
Read Full Article Article Summary

Lilly in Deal for Rights to BioMS Medical MS Drug - Therapeutics Daily

Reuters Health - Dec. 18, 2007
NEW YORK (Reuters) - Eli Lilly and Co said on Monday it has entered a deal that gives it exclusive worldwide rights to an experimental multiple sclerosis drug being developed by Canada's BioMS Medical Corp.
The drug, MBP8298, is currently in late-stage clinical trials for secondary progressive multiple sclerosis (MS) and in mid-stage trials for relapsing-remitting MS, the companies said.
BioMS Medical will receive an upfront payment of $87 million, potential development and sales milestones up to $410 million and escalating royalties on sales if the drug is approved.
Lilly and BioMS Medical will collaborate on the development of MBP8298 and will share in certain development costs, while Lilly will be responsible for future research and development, manufacturing and marketing, the companies said.
"MBP8298 has shown potential in slowing the progression of secondary progressive MS, and thus may provide an effective therapeutic option for patients with this debilitating disease," Dr William Chin, Lilly's vice president of discovery research and clinical investigation, said in a statement.
"We are also hopeful that MBP8298 may prove beneficial in treating patients with relapsing remitting MS," Chin said. "We intend to fully leverage our expertise in neuroscience to continue the development of this novel molecule."
The deal is expected to be finalized in the first quarter of 2008. Lilly said it expects to take a charge to earnings of about 5 cents per share at closing of the deal.
Lilly said its 2008 pro forma adjusted earnings forecast remains unchanged at $3.85 to $4.00 per share. Including the charge for the transaction with BioMS Medical, Lilly now expects 2008 earnings of $3.80 to $3.95 per share.
Analysts on average expect the company to earn $3.88 per share in 2008, according to Reuters Estimates.
(Reporting by Bill Berkrot, editing by Tim Dobbyn)
http://www.therapeuticsdaily.com/news/article.cfm?contentvalue=1647739&contenttype=sentryarticle&channelID=30